A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Clinical trial NCT05774951 · RECRUITING

Trial details

NCT number: NCT05774951
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer, Early Breast Cancer

Start date: 2023-03-31
Primary completion: 2027-04-20
Enrollment: 4300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.